The plasminogen activator system: Biology and regulation

Cellular and Molecular Life Sciences

Volumn 56, Issue 1-2, 1999, Pages 104-132

  Irigoyen, J P ^a   Munoz Canoves P ^b   Montero, L ^a   Koziczak, M ^a   Nagamine, Y ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b Institut de Recerca Oncologica   (Spain)

Author keywords

Cell invasion; Cell motility; Fibrinolysis; Metastasis; mRNA stability; Plasminogen activator; Plasminogen activator inhibitor; Signal transduction; Transcriptional regulation; uPA receptor

Indexed keywords

INTEGRIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

CELL MIGRATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMAN; MOLECULAR STABILITY; NONHUMAN; PLASMINOGEN ACTIVATION; PROTEIN DEGRADATION; REVIEW;

EID: 0033213996     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000615     Document Type: Review

References (412)

1. Robbins K. C., Summaria L., Hsieh B. and Shah R. J. (1967) The peptide chains of human plasmin: mechanism of activation of human plasminogen to plasmin. J. Biol. Chem. 242: 2333-2342
2. Raum D., Marcus D., Alper C. A., Levey R., Taylor P. D. and Starzl T. E. (1980) Synthesis of human plasminogen by the liver. Science 208: 1036-1037
3. Saksela O. and Vihko K. K. (1986) Local synthesis of plasminogen by the seminiferous tubules of the testis. FEBS Lett. 204: 193-197
4. Isseroff R. R. and Rifkin D. B. (1983) Plasminogen is present in the basal layer of the epidermis. J. Invest. Dermatol. 80: 297-299
5. Quigley J. P. (1979) Phorbol ester-induced morphological changes in transformed chick fibroblasts: evidence for direct catalytic involvement of plasminogen activator. Cell 17: 131-141
6. Salonen E. M., Zitting A. and Vaheri A. (1984) Laminin interacts with plasminogen and its tissue-type activator. FEBS Lett. 172: 29-32
7. Salonen E. M., Saksela O., Vartio T., Vaheri A., Nielsen L. S. and Zeuthen J. (1985) Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J. Biol. Chem. 260: 12302-12307
8. Lucas M. A., Fretto L. J. and McKee P. A. (1983) The binding of human plasminogen to fibrin and fibrinogen. J. Biol. Chem. 258: 4249-4256
9. Silverstein R. L., Leung L. L., Harpel P. C. and Nachman R. L. (1984) Complex formation of platelet thrombospondin with plasminogen: modulation of activation by tissue activator. J. Clin. Invest. 74: 1625-1633
10. Clemmensen I., Petersen L. C. and Kluft C. (1986) Purification and characterization of a novel, oligomeric. plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur. J. Biochem. 156: 327-333
11. Hembrough T. A., Vasudevan J., Allietta M. M., Glass W. F. 2nd and Gonias S. L. (1995) A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. J. Cell Sci. 108: 1071-1082
12. Silverstein R. L., Friedlander R. J. Jr., Nicholas R. L. and Nachman R. L. (1988) Binding of Lys-plasminogen to monocytes/macrophages. J. Clin. Invest. 82: 1948-1955
13. Miles L. A. and Plow E. F. (1987) Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells. Thromb. Haemost. 58: 936-942
14. Hajjar K. A., Harpel P. C., Jaffe E. A. and Nachman R. L. (1986) Binding of plasminogen to cultured human endothelial cells. J. Biol. Chem. 261: 11656-11662
15. Miles L. A., Dahlberg C. M., Plescia J., Felez J., Kato K. and Plow E. F. (1991) Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 30: 1682-1691
16. Hajjar K. A., Jacovina A. T. and Chacko J. (1994) An endothelial cell receptor for plasminogen tissue plasminogen activator. I. Identity with annexin II. J. Biol. Chem. 269: 21191-21197
17. Ellis V., Behrendt N. and Dano K. (1991) Plasminogen activation by receptor-bound urokinase: a kinetic study with both cell-associated and isolated receptor. J. Biol. Chem. 266: 12752-12758
18. Liotta L. A., Goldfarb R. H., Brundage R., Siegal G. P., Terranova V. and Garbisa S. (1981) Effect of plasminogen activator (urokinase) plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 41: 4629-4636
19. Chain D., Kreizman T., Shapira H. and Shaltiel S. (1991) Plasmin cleavage of vitronectin: identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett. 285: 251-256
20. Mochan E. and Keler T. (1984) Plasmin degradation of cartilage proteoglycan. Biochim. Biophys. Acta 800: 312-315
21. Dudek G. A., Kloczewiak M., Budzynski A. Z., Latallo Z. S. and Kopec M. (1970) Characterisation and comparison of macromolecular end products of fibrinogen and fibrin proteolysis by plasmin. Biochim. Biophys. Acta 214: 44-51
22. Goldfarb R. H., Murano G., Brundage R., Siegal G. P., Terranova V., Garbisa S. et al. (1986) Degradation of glycoprotein and collagenous components of the basement membrane: studies with urokinase-type plasminogen activator, alpha-thrombin, and plasmin. Semin. Thromb. Hemost. 12: 335-336
23. Vassalli J. D., Sappino A. P. and Belin D. (1991) The plasminogen activator plasmin system. J. Clin. Invest. 88: 1067-1072
24. Corcoran M. L., Hewitt R. E., Kleiner D. F., Jr. and Stetler-Stevenson W. G. (1996) MMP-2: expression, activation and inhibition. Enzyme Protein 49: 7-19
25. Keski-Oja J., Lohi J., Tuuttila A., Tryggvason K. and Vartio T. (1992) Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp. Cell Res. 202: 471-476
26. Taipale J., Koli K. and Keski-Oja J. (1992) Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J. Biol. Chem. 267: 25378-25384
27. Falcone D. J., McCaffrey T. A., Haimovitz-Friedman A., Vergilio J. A. and Nicholson A. C. (1993) Macrophage and foam cell release of matrix-bound growth factors: role of plasminogen activation. J. Biol. Chem. 268: 11951-11958
28. Ellis V., Scully M. F. and Kakkar V. V. (1989) Plasminogen activation initiated by single-chain urokinase-type plasminogen activator: potentiation by U937 monocytes. J. Biol. Chem. 264: 2185-2188
29. Stephens R. W., Pollanen J., Tapiovaara H., Leung K. C., Sim P. S., Salonen E. M. et al. (1989) Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J. Cell Biol. 108: 1987-1995
30. Bugge T. H., Flick M. J., Daugherty C. C. and Degen J. L. (1995) Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9: 794-807
31. Romer J., Bugge T. H., Pyke C., Lund L. R., Flick M. J., Degen J. L. et al. (1996) Impaired wound healing in mice with a disrupted plasminogen gene. Nat. Med. 2: 287-292
32. Bugge T. H., Kombrinck K. W., Flick M. J., Daugherty C. C., Danton M. J. and Degen J. L. (1996) Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87: 709-719
33. Bugge T. H., Flick M. J., Danton M. J., Daugherty C. C., Romer J., Dano K. et al. (1996) Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA 93: 5899-5904
34. Gunzler W. A., Steffens G. J., Otting F., Kim S. M., Frankus E. and Flohe L. (1982) The primary structure of high molecular mass urokinase from human urine: the complete amino acid sequence of the A chain. Hoppe Seylers Z. Physiol. Chem. 363: 1155-1165
35. Dano K., Andreasen P. A., Grondahl-Hansen J., Kristensen P., Nielsen L. S. and Skriver L. (1985) Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44: 139-266
36. Andreasen P. A., Kjoller L., Christensen L. and Duffy M. J. (1997) The urokinase-type plasminogen activator system in cancer metastasis; a review. Int. J. Cancer 72: 1-22
37. Petersen L. C., Lund L. R., Nielsen L. S., Dano K. and Skriver L. (1988) One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. Biol. Chem. 263: 11189-11195
38. Stoppelli M. P., Tacchetti C., Cubellis M. V., Corti A., Hearing V. J., Cassani G. et al. (1986) Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45: 675-684
39. Duval-Jobe C. and Parmely M. J. (1994) Regulation of plasminogen activation by human U937 promonocytic cells. J. Biol. Chem. 269: 21353-21357
40. Pennica D., Holmes W. E., Kohr W. J., Harkins R. N., Vehar G. A., Ward C. A. et al. (1983) Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301: 214-221
41. Strassburger W., Wollmer A., Pitts J. E., Glover I. D., Tickle I. J., Blundell T. L. et al. (1983) Adaptation of plasminogen activator sequences to known protease structures. FEBS Lett. 157: 219-223
42. Steffens G. J., Gunzler W. A., Otting F., Frankus E. and Flohe L. (1982) The complete amino acid sequence of low molecular mass urokinase from human urine. Hoppe Seylers Z. Physiol. Chem. 363: 1043-1058
43. Appella E., Robinson E. A., Ullrich S. J., Stoppelli M. P., Corti A., Cassani G. et al. (1987) The receptor-binding sequence of urokinase: a biological function for the growth-factor module of proteases. J. Biol. Chem. 262: 4437-4440
44. Stump D. C., Lijnen H. R. and Collen D. (1986) Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J. Biol. Chem. 261: 17120-17126
45. Naldini L., Tamagnone L., Vigna E., Sachs M., Hartmann G., Birchmeier W. et al. (1992) Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 11: 4825-4833
46. Mars W. M., Zarnegar R. and Michalopoulos G. K. (1993) Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am. J. Pathol. 143: 949-958
47. Keski-Oja J. and Vaheri A. (1982) The cellular target for the plasminogen activator, urokinase, in human fibroblasts 66,000 dalton protein. Biochim. Biophys. Acta 720: 141-146
48. Andreasen P. A., Riccio A., Welinder K. G., Douglas R., Sartorio R., Nielsen L. S. et al. (1986) Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett. 209: 213-218
49. Nielsen L. S., Andreasen P. A., Grondahl-Hansen J., Skriver L. and Dano K. (1986) Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass. FEBS Lett. 196: 269-273
50. Stoppelli M. P., Corti A., Soffientini A., Cassani G., Blast F. and Assoian R. K. (1985) Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA. 82: 4939-4943
51. Vassalli J. D., Baccino D. and Belin D. (1985) A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100: 86-92
52. Nienaber V. L., Young S. L., Birktoft J. J., Higgins D. L. and Berliner L. J. (1992) Conformational similarities between one-chain and two-chain tissue plasminogen activator (t-PA): implications to the activation mechanism on one-chain t-PA. Biochemistry 31: 3852-3861
53. Zonneveld A. J. van, Veerman H. and Pannekoek H. (1986) Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA 83: 4670-4674
54. Zonneveld A. J. van, Veerman H. and Pannekoek H. (1986) On the interaction of the linger and the kringle-2 domain of tissue-type plasminogen activator with fibrin: inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. J. Biol. Chem. 261: 14214-14218
55. Kuiper J., Otter M., Voorschuur A. H., Zonneveld A. J. van, Rijken D. C. and Berkel T. J. van (1995) Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type I with rat liver cells. Thromb. Haemost. 74: 1298-1304
56. Bakhit C., Lewis D., Billings R. and Malfroy B. (1987) Cellular catabolism of recombinant tissue-type plasminogen activator: identification and characterization of a novel high affinity uptake system on rat hepatocytes. J. Biol. Chem. 262: 8716-8720
57. 125I-tissue plasminogen activator binding to cerebellar granule neurons. J. Cell Biol. 109: 265-271
58. Fukao H., Ueshima S., Takaishi T., Okada K. and Matsuo O. (1997) Enhancement of tissue-type plasminogen activator (t-PA) activity by purified t-PA receptor expressed in human endothelial cells. Biochim. Biophys. Acta 1356: 111-120
59. Carroll P. M., Richards W. G., Darrow A. L., Wells J. M. and Strickland S. (1993) Preimplantation mouse embryos express a cell surface receptor for tissue-plasminogen activator. Development 119: 191-198
60. Bu G., Maksymovitch E. A., Nerbonne J. M. and Schwartz A. L. (1994) Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. J. Biol. Chem. 269: 18521-18528
61. Lijnen H. R. and Collen D. (1982) Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. Semin. Thromb. Hemost. 8: 2-10
62. Kooistra T., Schrauwen Y., Arts J. and Emeis J. J. (1994) Regulation of endothelial cell t-PA synthesis and release. Int. J. Hematol. 59: 233-255
63. Schneiderman J., Adar R. and Savion N. (1991) Changes in plasmatic tissue-type plasminogen activator and plasminogen activator inhibitor activity during acute arterial occlusion associated with severe ischemia. Thromb. Res. 62: 401-408
64. Grondahl-Hansen J., Lund L. R., Ralfkiaer E., Ottvanger V. and Dano K. (1988) Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J. Invest. Dermatol. 90: 790-795
65. Deutinger J., Kirchheimer J. C., Reinthaller A., Christ G., Tatra G. and Binder B. R. (1988) Elevated tissue type plasminogen activator in human granulosa cells correlates with fertilizing capacity. Hum. Reprod. 3: 597-599
66. Canipari R., O'Connell M. L., Meyer G. and Strickland S. (1987) Mouse ovarian granulosa cells produce urokinase-type plasminogen activator, whereas the corresponding rat cells produce tissue-type plasminogen activator. J. Cell Biol. 105: 977-981
67. Chapman H. A. Jr., Vavrin Z. and Hibbs J. B. Jr. (1982) Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell 28: 653-662
68. Andreasen P. A., Sottrup-Jensen L., Kjoller L., Nykjaer A., Moestrup S. K., Petersen C. M. et al. (1994) Receptor-mediated endocytosis of plasminogen activators and activator inhibitor complexes. FEBS Lett. 338: 239-245
69. Kawano T., Morimoto K. and Uemura Y. (1970) Partial purification and properties of urokinase inhibitor from human placenta. J. Biochem. (Tokyo) 67: 333-342
70. Loskutoff D. J. and Edgington T. E. (1977) Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc. Null. Acad. Sci. USA 74: 3903-3907
71. Baker J. B., Low D. A., Simmer R. L. and Cunningham D. D. (1980) Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 21: 37-45
72. Heeb M. J., Espana F., Geiger M., Collen D., Stump D. C. and Griffin J. H. (1987) Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J. Biol. Chem. 262: 15813-15816
73. Potempa J., Korzus E. and Travis J. (1994) The serpin superfamily of roteinase inhibitors: structure, function, and regulation. J. Biol. Chem. 269: 15957-15960
74. Ehrlich H. J., Keijer J., Preissner K. T., Gebbink R. K. and Pannekoek H. (1991) Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry 30: 1021-1028
75. Deng G., Royle G., Seiffert D. and Loskutoff D. J. (1995) The PAI-1/vitronectin interaction: two cats in a bag? Thromb. Haemost. 74: 66-70
76. Cubellis M. V., Andreasen P., Ragno P., Mayer M., Dano K. and Blasi F. (1989) Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA 86: 4828-4832
77. Laiho M., Saksela O. and Keski-Oja J. (1987) Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor: pericellular deposition and sensitivity to exogenous urokinase. J. Biol. Chem. 262: 17467-17474
78. Planus E., Barlovatz-Meimon G., Rogers R. A., Bonavaud S., Ingber D. E. and Wang N. (1997) Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J. Cell Sci. 110: 1091-1098
79. Nykjaer A., Conese M., Christensen E. I., Olson D., Cremona O., Gliemann J. et al. (1997) Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16: 2610-2620
80. Antalis T. M., Clark M. A., Barnes T., Lehrbach P. R., Devine P. L., Schevzov G. et al. (1988) Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA 85: 985-989
81. Ellis V., Wun T. C., Behrendt N., Ronne E. and Dano K. (1990) Inhibition of receptor-bound urokinase by plasminogen activator inhibitors. J. Biol. Chem. 265: 9904-9908
82. Kruithof E. K., Baker M. S. and Bunn C. L. (1995) Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86: 4007-4024
83. Kumar S. and Baglioni C. (1991) Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J. Biol. Chem. 266: 20960-20964
84. Dickinson J. L., Bates F. J., Ferrante A. and Antalis T. M. (1995) Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis: evidence for an alternate biological function. J. Biol. Chem. 270: 27894-27904
85. Antalis T. M., La Linn M., Donnan K., Mateo L., Gardner J., Dickinson J. L. et al. (1998) The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming. J. Exp. Med. 187: 1799-1811
86. Gan H., Newman G. W. and Remold H. G. (1995) Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with Mycobacterium arium, serovar 4. J. Immunol. 155: 1304-1315
87. Ploug M., Ronne E., Behrendt N., Jensen A. L., Blasi F. and Dano K. (1991) Cellular receptor for urokinase plasminogen activator: carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J. Biol. Chem. 266: 1926-1933
88. Ploug M. and Ellis V. (1994) Structure-function relationships in the receptor for urokinase-type plasminogen activator: comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett. 349: 163-168
89. Kristensen P., Eriksen J., Blasi F. and Dano K. (1991) Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J. Cell Biol. 115: 1763-1771
90. Hoyer-Hansen G., Ronne E., Solberg H., Behrendt N., Ploug M., Lund L. R. et al. (1992) Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267: 18224-18229
91. Solberg H., Romer J., Brunner N., Holm A., Sidenius N., Dano K. et al. (1994) A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int. J. Cancer 58: 877-881
92. Cubellis M. V., Nolli M. L., Cassani G. and Blasi F. (1986) Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J. Biol. Chem. 261: 15819-15822
93. Cubellis M. V., Wun T. C. and Blasi F. (1990) Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 9: 1079-1085
94. Conese M., Olson D. and Blasi F. (1994) Protease nexin-I-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor. J. Biol. Chem. 269: 17886-17892
95. Nykjaer A., Petersen C. M., Moller B., Jensen P. H., Moestrup S. K., Holtet T. L. et al. (1992) Purified alpha 2-macroglobulin receptor LDL receptor-related protein binds urokinase-plasminogen activator inhibitor type-1 complex: evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J. Biol. Chem. 267: 14543-14546
96. Conese M., Nykjaer A., Petersen C. M., Cremona O., Pardi R., Andreasen P. A. et al. (1995) Alpha-2 macroglobulin receptor Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J. Cell Biol. 131: 1609-1622
97. Goretzki L. and Mueller B. M. (1997) Receptor-mediated endocytosis of urokinase-type plasminogen activator is regulated by cAMP-dependent protein kinase. J. Cell Sci. 110: 1395-1402
98. Plow E. F., Freaney D. E., Plescia J. and Miles L. A. (1986) The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol. 103: 2411-2420
99. Blasi F., Vassalli J.-D. and Dano K. (1987) Urokinase-type plasminogen activator; proenzyme, receptor, and inhibitors. J. Cell Biol. 104: 801-804
100. Blasi F. and Verde P. (1990) Urokinase-dependent cell surface proteolysis and cancer. Semin. Cancer Biol. 1: 117-126
101. Mignatti P., Robbins E. and Rifkin D. B. (1986) Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47: 487-498
102. Cajot J. F., Schleuning W. D., Medcalf R. L., Bamat J., Testuz J., Liebermann L. et al. (1989) Mouse I. cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion. J. Cell Biol. 109: 915-925
103. Hollas W., Blasi F. and Boyd D. (1991) Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer. Res. 51: 3690-3695
104. Laug W. E., Cao X. R., Yu Y. B., Shimada H. and Kruithof E. K. (1993) Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res. 53: 6051-6057
105. Quattrone A., Fibbi G., Anichini E., Pucci M., Zamperini A., Capaccioli S. et al. (1995) Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res. 55: 90-95
106. Romer J., Lund L. R., Eriksen J., Pyke C., Kristensen P. and Dano K. (1994) The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J. Invest. Dermatol. 102: 519-522
107. Schafer B. M., Maier K., Eickhoff U., Todd R. F. and Kramer M. D. (1994) Plasminogen activation in healing human wounds. Am. J. Pathol. 144: 1269-1280
108. Politis I. (1996) Plasminogen activator system: implications for mammary cell growth and involution. J. Dairy Sci. 79: 1097-1107
109. Liu G., Shuman M. A. and Cohen R. L. (1995) Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer 60: 501-506
110. Pappot H., Gardsvoll H., Romer J., Pedersen A. N., Grondahl-Hansen J., Pyke C. et al. (1995) Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol. Chem. Hoppe Seyler 376: 259-267
111. Bajou K., Noel A., Gerard R. D., Masson V., Brunner N., Holst-Hansen C. et al. (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4: 923-928
112. Olson D., Pollanen J., Hoyer-Hansen G., Ronne E., Sakaguchi K., Wun T. C. et al. (1992) Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J. Biol. Chem. 267: 9129-9133
113. Preissner K. T. (1991) Structure and biological role of vitronectin. Annu. Rev. Cell Biol. 7: 275-310
114. Felding-Habermann B. and Cheresh D. A. (1993) Vitronectin and its receptors. Curr. Opin. Cell Biol. 5: 864-868
115. Preissner K. T., Anders E., Grulich-Henn J. and Muller-Berghaus G. (1988) Attachment of cultured human endothelial cells is promoted by specific association with S protein (vitronectin) as well as with the ternary S protein-thrombin-antithrombin III complex. Blood 71: 1581-1589
116. Mimuro J. and Loskutoff D. J. (1989) Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix: evidence that the protein is vitronectin. J. Biol. Chem. 264: 936-939
117. 3, binding to vitronectin. Nature 383: 441-443
118. Waltz D. A. and Chapman H. A. (1994) Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 269: 14746-14750
119. Wei Y., Waltz D. A., Rao N., Drummond R. J., Rosenberg S. and Chapman H. A. (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269: 32380-32388
120. Moser T. L., Enghild J. J., Pizzo S. V. and Stack M. S. (1995) Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem. J. 307: 867-873
121. Kanse S., Kost C., Wilhelm O., Andreasen P. and Preissner K. (1996) The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224: 344-353
122. Higazi A. A., Upson R. H., Cohen R. L., Manuppello J., Bognacki J., Henkin J. et al. (1996) Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood 88: 542-551
123. Deng G., Curriden S. A., Wang S., Rosenberg S. and Loskutoff D. J. (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134: 1563-1571
124. Chapman H. A. (1997) Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9: 714-724
125. Kjoller L., Kanse S. M., Kirkegaard T., Rodenburg K. W., Ronne E., Goodman S. L. et al. (1997) Plasminogen activator inhibitor-1 represses integrin- and vitronectin- mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 232: 420-429
126. Waltz D. A., Natkin L. R., Fujita R. M., Wei Y. and Chapman H. A. (1997) Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin, J. Clin. Invest. 100: 58-67
127. Franco P., Iaccarino C., Chiaradonna F., Brandazza A., Iavarone C., Mastronicola M. R. et al. (1997) Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J. Cell Biol. 137: 779-791
128. Franco P., Massa O., Garcia-Rocha M., Chiaradonna F., Iaccarino C., Correas I. et al. (1998) Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist. J. Biol. Chem. 273: 27734-27740
129. Gumbiner B. M. (1996) Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 84: 345-357
130. Myohanen H. T., Stephens R. W., Hedman K., Tapiovaara H., Ronne E., Hoyer-Hansen G. et al. (1993) Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J. Histochem. Cytochem. 41: 1291-1301
131. Wei Y., Lukashev M., Simon D. I., Bodary S. C., Rosenberg S., Doyle M. V. et al. (1996) Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555
132. Okamoto T., Schlegel A., Scherer P. E. and Lisanti M. P. (1998) Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' al the plasma membrane. J. Biol. Chem. 273: 5419-5422
133. Kindzelskii A. L., Laska Z. O., Todd R. F. 3rd and Petty H. R. (1996) Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2′ CD11b/CD18) during neutrophil polarisation. J. Immunol. 156: 297-309
134. Todd R. F. 3rd and Petty H. R. (1997) Beta 2 (CD11/CD18) integrins can serve as signaling partners for other leukocyte receptors. J. Lab. Clin. Med. 129: 492-498
135. Xuc W., Mizukami I., Todd R. F. 3rd and Petty H. R. (1997) Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 57: 1682-1689
136. Yebra M., Parry G. C. N., Stromblad S., Mackman N., Rosenberg S., Mueller B. M. et al. (1996) Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J. Biol. Chem. 271: 29393-29399
137. Gyetko M. R., Chen G. H., McDonald R. A., Goodman R., Huffnagle G. B., Wilkinson C. C. et al. (1996) Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans: a murine transgenic model. J. Clin. Invest. 97: 1818-1826
138. Gudewicz P. W. and Gilboa N. (1987) Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem. Biophys. Res. Commun. 147: 1176-1181
139. Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F. and Fazioli F. (1996) Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15: 1572-1582
140. Fazioli F., Resnati M., Sidenius N., Higashimoto Y., Appella E. and Blasi F. (1997) A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16: 7279-7286
141. Ulevitch R. J. and Tobias P. S. (1995) Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13: 437-457
142. Bohuslav J., Horejsi V., Hansmann C., Stockl J., Weidle U. H., Majdic O. et al. (1995) Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181: 1381-1390
143. Stahl A. and Mueller B. M. (1995) The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J. Cell Biol. 129: 335-344
144. Koshelnick Y., Ehart M., Hufnagl P., Heinrich P. C. and Binder B. R. (1997) Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272: 28563-28567
145. Dumler I., Weis A., Mayboroda O. A., Maasch C., Jerke U., Haller H. et al. (1998) The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J. Biol. Chem. 273: 315-321
146. Konakova M., Hucho F. and Schleuning W. D. (1998) Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur. J. Biochem, 253: 421-429
147. Tang H., Kerins D. M., Hao Q., Inagami T. and Vaughan D. E. (1998) The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 273: 18268-18272
148. Busso N., Masur S. K., Lazega D., Waxman S. and Ossowski L. (1994) Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126: 259-270
149. Cai H., Erhardt P., Troppmair J., Diaz-Meco M. T., Sithanandam G., Rapp U. R. et al. (1993) Hydrolysis of phosphatidylcholine couples Ras to activation of Raf protein kinase during mitogenic signal transduction. Mol. Cell Biol. 13: 7645-7651
150. Nguyen D. H., Hussaini I. M. and Gonias S. L. (1998) Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 273: 8502-8507
151. Dear A. E., Costa M. and Medcalf R. L. (1997) Urokinase-mediated transactivation of the plasminogen activator inhibitor type 2 (PAI-2) gene promoter in HT-1080 cells utilises AP-1 binding sites and potentiates phorbol ester-mediated induction of endogenous PAI-2 mRNA. FEBS Lett. 402: 265-272
152. Rabbani S. A., Gladu J., Mazar A. P., Henkin J. and Goltzman D. (1997) Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J. Cell Physiol. 172: 137-145
153. Bini A. and Kudryk B. J. (1994) Fibrinogen and fibrin in the arterial wall. Thromb. Res. 75: 337-341
154. Blomback B. (1996) Fibrinogen and fibrin proteins with complex roles in hemostasis and thrombosis. Thromb. Res. 83: 1-75
155. Lamarche B. (1998) Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coronary Artery Dis. 9: 473-481
156. Sowers J. R. (1998) Obesity and cardiovascular disease. Clin. Chem. 44: 1821-1825
157. Juhan-Vague I. and Alessi M. C. (1997) PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb. Haemost. 78: 656-660
158. Loskutoff D. J. and Samad F. (1998) The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioseler. Thromb. Vasc. Biol. 18: 1-6
159. Duffy M. J., Reiffy D., O'Sullivan C., O'Higgins N., Fennelly J. J. and Andreasen P. (1990) Urokinase-plasminogen activator, a new independent prognostic marker in breast cancer. Cancer Res. 50: 6827-6829
160. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U. et al. (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78: 285-296
161. Blasi F. (1988) Surface receptors for urokinase plasminogen activator. Fibrinolysis 2: 73-84
162. Carmeliet P. and Coolen D. (1996) Targeted gene manipulation and transfer of the plasminogen and coagulation system in mice. Fibrinolysis 10: 195-213
163. Carmeliet P., Moons L. and Collen D. (1998) Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc. Res. 39: 8-33
164. Johnsen M., Lund L. R., Romer J., Almholt K. and Dano K. (1998) Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr. Opin. Cell Biol. 10: 667-671
165. Bugge T. H., Kombrinck K. W., Xiao Q., Holmback K., Daugherty C. C., Witte D. P. et al. (1997) Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 90: 4522-4531
166. Tsirka S. E., Rogove A. D., Bugge T. H., Degen J. L. and Strickland S. (1997) An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J. Neurosci. 17: 543-552
167. Xiao Q., Danton M. J., Witte D. P., Kowala M. C., Valentine M. T., Bugge T. H. et al. (1997) Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc. Natl. Acad. Sci. USA 94: 10335-10340
168. Bugge T. H., Lund L. R., Kombrinck K. K., Nielsen B. S., Holmback K., Drew A. F. et al. (1998) Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16: 3097-3104
169. Drew A. F., Kaufman A. H., Kombrinck K. W., Danton M. J., Daugherty C. C., Degen J. L. et al. (1998) Ligneous conjunctivitis in plasminogen-deficient mice. Blood 91: 1616-1624
170. Nagamine Y., Pearson D., Altus M. S. and Reich F. (1984) cDNA and gene nucleotide sequence of porcine plasminogen activator. Nucleic Acids Res. 12: 9525-9541
171. Riccio A., Grimaldi G., Verde P., Sebastio G., Boast S. and Blasi F. (1985) The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res. 13: 2759-2771
172. Degen S. L., Heekel J. L., Reich E. and Degen J. L. (1987) The murine urokinase-type plasminogen activator gene. Biochemistry 26: 8270-8279
173. Ahe D. von der, Pearson D., Nakagawa J., Rajput B. and Nagamine Y. (1988) Multiple nuclear factors interact with promoter sequences of the urokinase-type plasminogen activator gene. Nucleic Acids Res. 16: 7527-7544
174. Nagamine Y., Lee J. S., Menoud P.-A. and Nanbu R. (1995) Structure and function of the urokinase-type plasminogen activator gene. In: Fibrinolysis in Disease. pp 10-20, Glas-Grenwalt P. (ed.), CRC, Boca Raton.
175. Besser D., Verde P., Nagamine Y. and Blasi F. (1996) Signal transduction and the u-PA u-PAR system. Fibrinolysis 10: 215-237
176. Verde P., Boast S., Franze A., Robbiati F. and Blasi F. (1988) An upstream enhancer and a negative clement in the 5′ flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res. 16: 10699-10716
177. Cassady A. I., Stacey K. J., Nimmo K. A., Murphy K. M., Ahe D. von der, Pearson D. et al. (1991) Constitutive expression of the urokinase plasminogen activator gene in murine Raw264 macrophages involves distal and 5′ non-coding sequences that are conserved between mouse and pig. Nucleic Acids Res. 19: 6839-6847
178. Nerlov C., De Cesare D., Pergola F., Caracciolo A., Blasi F., Johnsen M. et al. (1992) A regulatory element that mediates co-operation between a PEA3-AP-1 clement and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J. 11: 4573-4582
179. Rorth P., Nerlov C., Blasi F. and Johnsen M. (1990) Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester. Nucleic Acids Res. 18: 5009-5017
180. Sharrocks A. D., Brown A. L., Ling Y. and Yates P. R. (1997) The ETS-domain transcription factor family. Int. J. Biochem. Cell Biol. 29: 1371-1387
181. Wasylyk B., Hagman J. and Gutierrez-Hartmann A. (1998) Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem. Sci. 23: 213-216
182. Stacey K. J., Fowles L. F., Colman M. S., Ostrowski M. C. and Hume D. A. (1995) Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. Mol. Cell Biol. 15: 3430-3441
183. D'Orazio D., Besser D., Marksitzer R., Kunz C., Hume D. A., Kiefer B., et al. (1997) Cooperation of two PEA3 API sites in uPA gene induction by TPA and FGF-2. Gene 201: 179-187
184. Delannoy-Courdent A., Mattot V., Fafeur V., Fauquette W., Pollet I., Calmels T. et al. (1998) The expression of an Ets1 transcription factor lacking its activation domain decreases uPA proteolytic activity and cell motility, and impairs normal tubulogenesis and cancerous scattering in mammary epithelial cells. J. Cell Sci. 111: 1521-1534
185. Watabe T., Yoshida K., Shindoh M., Kaya M., Fujikawa K., Sato H. et al. (1998) The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int. J. Cancer 77: 128-137
186. Lengyel E., Klostergaard J. and Boyd D. (1995) Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. Biochim. Biophys. Acta 1268: 65-72
187. De Cesare D., Palazzolo M., Berthelsen J. and Blasi F. (1997) Characterization of UEF-4, a DMA-binding protein required for transcriptional synergism between two AP-1 sites in the human urokinase enhancer. J. Biol. Chem. 272: 23921-23929
188. Berthelsen J., Vandekerkhove J. and Blasi F. (1996) Purification and characterization of UEF3, a novel factor involved in the regulation of the urokinase and other AP 1 controlled promoters. J. Biol. Chem. 271: 3822-3830
189. Vandenbunder B., Queva C., Desbiens X., Wernert N. and Stehelin D. (1994) Expression of the transcription factor c-Ets1 correlates with the occurrence of invasive processes during normal and pathological development. Invasion Metastasis 14: 198-209
190. Bolon I., Gouyer V., Devouassoux M., Vandenbunder B., Wernert N., Moro D. et al. (1995) Expression of c-ets-1. collagenase I, and urokinase-type plasminogen activator genes in lung carcinomas. Am. J. Pathol. 147: 1298-1310
191. Delannoy-Courdent A., Fauquette W., Dong-Le Bourhis X. F., Boilly B., Vandenbunder B. and Desbiens X. (1996) Expression of c-ets-1 and uPA genes is associated with mammary epithelial cell tubulogenesis or neoplastic scattering. Int. J. Dev. Biol. 40: 1097-1108
192. Iwasaka C., Tanaka K., Abe M. and Sato Y. (1996) Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metallo-proteinase-1 and the migration of vascular endothelial cells. J. Cell Physiol. 169: 522-531
193. Chen Z., Fisher R. J., Riggs C. W., Rhim J. S. and Lautenberger J. A. (1997) Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETSI antisense oligonucleotides. Cancer Res. 57: 2013-2019
194. Angel P., Imagawa M., Chiu R., Stein B., Imbra R. J., Rahmsdorf H. J. et al. (1987) Phorbol ester-inducible genes contain a common cis clement recognized by a TPA-modulated trans-acting factor. Cell 49: 729-739
195. Lee W., Mitchell P. and Tjian R. (1987) Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 49: 741-752
196. Angel P. and Karin M. (1991) The role of Jun. Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Act a 1072: 129-157
197. Woodgett J. R. (1990) Fos and jun: two into one will go. Semin. Cancer Biol. 1: 389-397
198. Benbrook D. M. and Jones N. C. (1990) Heterodimer formation between CREB and JUN proteins. Oncogene 5: 295-302
199. Hai T. and Curran T. (1991) Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl. Acad. Sci. USA 88: 3720-3724
200. Karin M., Liu Z. and Zandi E. (1997) AP-1 function and regulation. Curr. Opin. Cell Biol. 9: 240-246
201. Yang B., Hauser C., Henkel G., Colman M., Van B. C., Stacey K. et al. (1996) Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell Biol. 16: 538-547
202. McCarthy S. A., Chen D., Yang B. S., Garcia Ramirez J. J., Cherwinski H., Chen X. R. et al. (1997) Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol. Cell Biol. 17: 2401-2412
203. Hibi M., Lin A., Smeal T., Minden A. and Karin M. (1993) Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7: 2135-2148
204. Derijard B., Hibi M., Wu I. H., Barrett T., Su B., Deng T. et al. (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037
205. Karin M. (1996) The regulation of AP-I activity by mitogen-activated protein kinases. Philos. Trans. R. Soc. Lond. B. 351: 127-134
206. Kallunki T., Deng T., Hibi M. and Karin M. (1996) c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 87: 929-939
207. Irigoyen J. P., Besser D. and Nagamine Y. (1997) Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/extracellular signal-regulated kinase (ERK) signaling pathway. J. Biol. Chem. 272: 1904-1909
208. Mendelson K. G., Contois L. R., Tevosian S. G., Davis R. J. and Paulson K. E. (1996) Independent regulation of JNK p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver. Proc. Natl. Acad. Sci. USA 93: 12908-12913
209. Gupta S., Campbell D., Derijard B. and Davis R. J. (1995) Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267: 389-393
210. Raingeaud J., Whitmarsh A. J., Barrett T., Derijard B. and Davis R. J. (1996) MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway Mol. Cell Biol. 16: 1247-1255
211. Paul A., Wilson S., Belham C. M., Robinson C. J., Scott P. H., Gould G. W. and Plevin R. (1997) Stress-activated protein kinases: activation, regulation and function. Cell Signal. 9: 403-410
212. Sugden P. H. and Clerk A. (1997) Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cell Signal. 9: 337-351
213. Ip Y. T. and Davis R. J. (1998) Signal transduction by the c-Jun N-terminal kinase (JNK) from inflammation to development. Curr. Opin. Cell Biol. 1: 205-219
214. Lewis T. S., Shapiro P. S. and Ahn N. G. (1998) Signal transduction through MAP kinase cascades. Adv. Cancer Res. 7: 49-139
215. Madhani H. D. and Fink G. R. (1998) The riddle of MAP kinase signaling specificity. Trends Genet. 14: 151-155
216. Lee J. S., Ahe D. von der, Kiefer B. and Nagamine Y. (1993) Cytoskeletal reorganization and TPA differently modify AP-1 to induce the urokinase-type plasminogen activator gene in LLC-PK1 cells. Nucleic Acids Res. 21: 3365-3372
217. Lee J. S., Favre B., Hemmings R. A., Kiefer B. and Nagamine Y. (1994) Okadaic acid-dependent induction of the urokinase-type plasminogen activator gene associated with stabilization and autoregulation of c-Jun. J. Biol. Chem. 269: 2887-2894
218. Besser D., Presta M. and Nagamine Y. (1995) Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth Differ. 6: 1009-1017
219. Besser D., Bardelli A., Didichenko S., Thelen M., Comoglio P. M., Ponzetto C. et al. (1997) Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. Oncogene 14: 705-711
220. Besser D., Urich M., Sakaue M., Messerschmitt A., Ballmer-Hofer K. and Nagamine Y. (1995) Urokinase-type plasminogen activator gene regulation by polyomavirus middle-T antigen. Oncogene 11: 2383-2391
221. Lengyel E., Singh B., Gum R., Nerlov C., Sabichi A., Birrer M. et al. (1995) Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene 11: 2639-2648
222. Miralles F., Parra M., Caelles C., Nagamine Y., Felez J. and Munoz-Canoves P. (1998) UV irradiation induces the murine urokinase-type plasminogen activator gene via the c-Jun N-terminal kinase signaling pathway: requirement of an API enhancer clement. Mol. Cell Biol. 18: 4537-4547
223. Gottlicher M., Rahmsdorf H. J. and Herrlich P. (1997) The AP-1 family of transcription factors: multi-level control of activity. In: Transcription Factors in Eukaryotes. pp 67-93, Papavassiliou A. G. (ed.), Landes Bioscience, Austin, Texas
224. Wulczyn F. G., Krappmann D. and Scheidereit C. (1996) The NF-kappa B. Rel and I kappa B gene families: mediators of immune response and inflammation. J. Mol. Med. 74: 749-769
225. Pahl H. L. and Bacuerle P. A. (1996) Control of gene expression by proteolysis. Curr. Opin. Cell Biol. 8: 340-347
226. Hansen S. K., Nerlov C., Zabel U., Verde P., Johnson M. et al. (1992) A novel complex between the p65 subunit of NF-kB and c-Rel binds to a DNA element involved in the phorbol ester induction or the human urokinase gene. EMBO J. 11: 205-213
227. Nagamine Y., Sudol M. and Reich P. (1983) Hormonal regulation of plasminogen activator mRNA production in porcine kidney cells. Cell 32: 1181-1190
228. Ahe D. von der, Pearson D. and Nagamine Y. (1990) Macromolecular interaction on a cAMP responsive region in the urokinase-type plasminogen activator gene: a role of protein phosphorylation. Nucleic Acids Res. 18: 1991-1999
229. Lee J. S., Catanzariti L., Hemmings B. A., Kiefer B. and Nagamine Y. (1994) Activation of cAMP-dependent protein kinase alters the chromatin structure of the urokinase-type plasminogen activator gene promoter. Nucleic Acids Res. 22: 569-575
230. Menoud P.-A., Matthies R., Hofsteenge J. and Nagamine Y. (1993) Purification and cDNA cloning of a transcription factor which functionally cooperates within a cAMP regulatory unit in the porcine uPA gene. Nucleic Acids Res. 21: 1845-1852
231. Marksitzer R., Stief A., Menoud P.-A. and Nagamine Y. (1995) Role of LFB3 in cell-specific cAMP induction of the urokinase-type plasminogen activator gene. J. Biol. Chem. 270: 21833-21838
232. Soubt M. K., Marksitzer R., Menoud P. A. and Nagamine Y. (1998) Role of tissue-specific transcription factor LFB3 in a cyclic AMP-responsive enhancer of the urokinase-type plasminogen activator gene in LLC-PK1 cells. Mol. Cell Biol. 18: 4698-4706
233. Fisher R., Waller E. K., Grossi G., Thompson D., Tizard R. and Schleuning W.-D. (1985) Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5′ flanking region. J. Biol. Chem. 260: 11223-11230
234. Degen S., J., Rajput B. and Reich E. (1986) The human tissue plasminogen activator gene. J. Biol. Chem. 261: 6972-6985
235. Rickles R. J., Darrow A. L. and Strickland S. (1989) Differentiation-responsive elements in the 5′ region of the mouse tissue plasminogen activator gene confer two-stage regulation by retinoic acid and cyclic AMP in teratocarcinoma cells. Mol. Cell Biol. 9: 1691-1704
236. Feng P., Ohlsson M. and Ny T. (1990) The structure of the TATA-less rat tissue-type plasminogen activator gene: species-specific sequence divergences in the promoter predict differences in regulation of gene expression. J. Biol. Chem. 265: 2022-2027
237. Kathju S., Heaton J. H., Bruzdzinski C. J. and Gelehrter T. D. (1994) Synergistic induction of tissue-type plasminogen activator gene expression by glucocorticoids and cyclic nucleotides in rat HTC hepatoma cells. Endocrinology 135: 1195-1204
238. Henderson B. R. and Sleigh M. J. (1992) TATA box-independent transcription of the human tissue plasminogen activator gene initiates within a sequence conserved in related genes. FEBS Lett. 309: 130-134
239. Bulens F., Ibanez-Tallon I., Van Acker P., De Vriese A., Nelles L., Belayew A. et al. (1995) Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DR5) located at - 7 kilobases. J. Biol. Chem. 270: 7167-7175
240. Leonardsson G. and Ny T. (1997) Characterisation of the rat tissue-type plasminogen activator gene promoter identification of a TAAT-containing promoter element. Eur. J. Biochem. 248: 676-683
241. Cousin E., Medcalf R. L., Bergonzelli G. E. and Kruithof E. K. (1991) Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoter. Nucleic Acids Res. 19: 3881-3886
242. Darrow A. L., Rickles R. J., Pecorino L. T. and Strickland S. (1990) Transcription Factor Sp1 is important for retinoic add-induced expression of the tissue plasminogen activator gene during F9 teratocarcinoma cell differentiation. Mol. Cell Biol. 10: 5883-5893
243. Medcalf R. L., Ruegg M. and Schleuning W. D. (1990) A DNA motif related to the cAMP-responsive element and an exon-located activator protein-2 binding site in the human tissue-type plasminogen activator gene promoter cooperate in basal expression and convey activation by phorbol ester and cAMP. J. Biol. Chem. 265: 14618-14626
244. Ohlsson M., Leonardsson G., Jia X. C., Feng P. and Ny T. (1993) Transcriptional regulation of the rat tissue type plasminogen activator gene: localization of DNA elements and nuclear factors mediating constitutive and cyclic AMP-induced expression. Mol. Cell Biol. 13: 266-275
245. Arts J., Herr I., Lansink M., Angel P. and Kooistra T. (1997) Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro. Nucleic Acids Res. 25: 311-317
246. Pecorino L. T., Darrow A. L. and Strickland S. (1991) In vitro analysis of the tissue plasminogen activator promoter reveals a GC box-binding activity present in murine brain but undetectable able in kidney and liver. Mol. Cell Biol. 11: 3139-3147
247. Holmberg M., Leonardsson G. and Ny T. (1995) The species-specific differences in the cAMP regulation of the tissue-type plasminogen activator gene between rat, mouse and human is caused by a one-nucleotide substitution in the cAMP-responsive clement of the promoters. Eur. J. Biochem. 231: 466-474
248. Rossi P., Grimaldi P., Blasi F., Geremia R. and Verde P. (1990) Follicle-stimulating hormone and cyclic AMP induce transcription from the human urokinase promoter in primary cultures of mouse Sertoli cells. Mol. Endocrinol. 4: 940-946
249. Costa M. and Medcalf R. L. (1996) Differential binding of cAMP-responsive-element (CRE)-binding protein-1 and activating transcription factor-2 to a CRE-like element in the human tissue-type plasminogen activator (t-PA) gene promoter correlates with opposite regulation of t-PA by phorbol ester in HT-1080 and HeLa cells. Eur. J. Biochem. 237: 532-538
250. Lamph W. W., Dwarki V. J., Ofir R., Montminy M. and Verma I. M. (1990) Negative and positive regulation by transcription factor cAMP response element-binding protein is modulated by phosphorylation. Proc. Natl. Acad. Sci. USA 87: 4320-4324
251. Gehring W. J., Affolter M. and Burglin T. (1994) Homeodomain proteins. Annu. Rev. Biochem. 63: 487-526
252. Gehring W. J., Qian Y. Q., Billeter M., Furukubo-Tokunaga K., Schier A. F., Resendez-Perez D. et al. (1994) Homeodomain-DNA recognition. Cell 78: 211-223
253. Krumlauf R. (1994) Hox genes in vertebrate development. Cell 78: 191-201
254. Belch J. J., Madhok R., McArdle B., McLaughlin K., Kluft C. et al. (1986) The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol. Q. J. Med. 58: 19-27
255. Medcalf R. L., Van den Berg E. and Schleuning W. D. (1988) Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2. J. Cell Biol. 106: 971-978
256. Wang C. and Leung A. (1989) Glucocorticoids stimulate plasminogen activator production by rat granulosa cells. Endocrinology 124: 1595-1601
257. Jia X. C., Ny T. and Hsueh A. J. (1990) Synergistic effect of glucocorticoids and androgens on the hormonal induction of tissue plasminogen activator activity and messenger ribonucleic acid levels in granulosa cells. Mol. Cell Endocrinol. 68: 143-151
258. Kooistra T., Opdenberg J. P., Toet K., Hendriks H. F., van den Hoogen R. M. and Emeis J. J. (1991) Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo. Thromb. Haemost. 65: 565-572
259. Bulens F., Thompson E. A., Stassen J.-M., Moreau H., Declerek P. J., Nelles L. et al. (1992) Induction of t-PA synthesis with intravenous bolus injection of vitamin A palmitate in vitamin deficient rats. Fibrinolysis 6: 243-249
260. Bulens E., Merchiers P., Ibanez-Tallon I., De Vriese A., Nelles L., Claessens F. et al. (1997) Identification of a multihormone responsive enhancer far upstream from the human tissue-type plasminogen activator gene. J. Biol. Chem. 272: 663-671
261. Hori R. and Carey M. (1994) The role of activators in assembly of RNA polymerase II transcription complexes. Curr. Opin. Genet. Dev. 4: 236-244
262. Mastrangelo I. A., Courey A. J., Wall J. S., Jackson S. P. and Hough P. V. (1991) DNA looping and Spl multimer links: a mechanism for transcriptional synergism and enhancement. Proc. Natl. Acad. Sci. USA 88: 5670-5674
263. Su W., Jackson S., Tjian R. and Echols H. (1991) DNA looping between sites for transcriptional activation: self-association of DNA-bound Spl. Genes Dev. 5: 820-826
264. Loskutoff D. J., Linders M., Keijer J., Veerman H., van Heerikhuizen H. and Pannekoek H. (1987) Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns. Biochemistry 26: 3763-3768
265. Bosma P. J., Berg E. A. van den, Kooistra T., Siemieniak D. R. and Slightom J. L. (1988) Human plasminogen activator inhibitor-1 gene: promoter and structural gene nucleotide sequences. J. Biol. Chem. 263: 9129-9141
266. Bruzdzinski C. J., Riordan-Johnson M., Nordby E. C., Suter S. M. and Gelehrter T. D. (1990) Isolation and characterization of the rat plasminogen activator inhibitor-1 gene. J. Biol. Chem. 265: 2078-2085
267. Prendergast G. C., Diamond L. E., Dahl D. and Cole M. D. (1990) The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol. Cell. Biol. 10: 1265-1269
268. Riccio A., Lund L. R., Sartorio R., Lania A., Andreasen P. A., Dano K. et al. (1988) The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene. Nucleic Acids Res. 16: 2805-2824
269. Descheemaeker K. A., Wyns S., Nelles L., Auwerx J., Ny T. and Collen D. (1992) Interaction of AP-1-, AP-2-, and Spl-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J. Biol. Chem. 267: 15086-15091
270. Johnson M. R., Bruzdzinski C. J., Winograd S. S. and Gelehrter T. D. (1992) Regulatory sequences and protein-binding sites involved in the expression of the rat plasminogen activator inhibitor-1 gene. J. Biol. Chem. 267: 12202-12210
271. Arts J., Grimbergen J., Bosma P. J., Rahmsdorf H. J. and Kooistra T. (1996) Role of c-Jun and proximal phorbol 12-myristate-13-acetate-(PMA)-responsive elements in the regulation of basal and PMA-stimulated plasminogen-activator inhibitor-1 gene expression in HepG2. Eur. J. Biochem. 241: 393-402
272. Santell L. and Levin E. G. (1988) Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 front human endothelial cells. J. Biol. Chem. 263: 16802-16808
273. Ding H., Descheemaeker K., Marynen P., Nelles L., Carvalho T., Carmo-Fonseca M. et al. (1996) Characterization of a helicase-like transcription factor involved in the expression of the human plasminogen activator inhibitor-1 gene. DNA Cell Biol. 15: 429-442
274. Zhang Q., Ekhterae D. and Kim K. H. (1997) Molecular cloning and characterization of PH3, a mouse SNF2/SWI2-related transcription factor. Gene 202: 31-37
275. Eisen J. A., Sweder K. S. and Hanawalt P. C. (1995) Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions. Nucleic Acids Res. 23: 2715-2723
276. Lund L. R., Riccio A., Andreasen P. A., Nielsen L. S., Kristensen P., Laiho M. et al. (1987) Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J. 6: 1281-1286
277. Keski-Oja J., Raghow R., Sawdey M., Loskutoff D. J., Postlethwaite A. E., Kang A. H. et al. (1988) Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type 1 procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J. Biol. Chem. 263: 3111-3115
278. Fujii S., Hopkins W. E. and Sobel B. E. (1991) Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation 83: 645-651
279. Abe M., Harpel J. G., Metz C. N., Nunes I., Loskutoff D. J. and Rifkin D. B. (1994) An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem. 216: 276-284
280. Westerhausen D. R. Jr., Hopkins W. E. and Billadello J. J. (1991) Multiple transforming growth factor-beta-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. J. Biol. Chem. 266: 1092-1100
281. Keeton M. R., Curriden S. A., Zonneveld A. J. van and Loskutoff D. J. (1991) Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J. Biol. Chem. 266: 23048-23052
282. Riccio A., Pedone P. V., Lund L. R., Olesen T., Olsen H. S. and Andreasen P. A. (1992) Transforming growth factor beta 1-responsive element: closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor 1 in the type 1 plasminogen activator inhibitor gene. Mol. Cell. Biol. 12: 1846-1855
283. Sandler M. A., Zhang J. N., Westerhausen D. R. Jr. and Billadello J. J. (1994) A novel protein interacts with the major transforming growth factor-beta responsive element in the plasminogen activator inhibitor type-1 gene. J. Biol. Chem. 269: 21500-21504
284. Dennler S., Itoh S., Vivien D., Dijke P. ten. Huet S. and Gauthier J. M. (1998) Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17: 3091-3100
285. Song C. Z., Siok T. E. and Gelehrter T. D. (1998) Smad4 DPC4 and Smad3 mediate transforming growth factor-beta (TGF-beta) signaling through direct binding to a novel TGF-beta-responsive element in the human plasminogen activator inhibitor-1 promoter. J. Biol. Chem. 273: 29287-29290
286. Zhang Y., Feng X. H. and Derynck R. (1998) Smad3 and Smad4 cooperate with c-Jun c-Fos to mediate TGF-beta-induced transcription. Nature 394: 909-913
287. Hua X., Liu X., Ansari D. O. and Lodish H. F. (1998) Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev. 12: 3084-3095
288. Feng X. H., Zhang Y., Wu R. Y. and Derynck R. (1998) The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev. 12: 2153-2163
289. Georg B., Riccio A. and Andreasen P. (1990) Forskolin down-regulates type-1 plasminogen activator inhibitor and tissue-type plasminogen activator and their mRNAs in human fibrosarcoma cells. Mol. Cell Endocrinol. 72: 103-110
290. Kooistra T., Bosma P. J., Toet K., Cohen L. H., Griffioen M., Berg E. van den et al. (1991) Role of protein kinase C and cyclic adenosine monophosphate in the regulation of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and platelet-derived growth factor mRNA levels in human endothelial cells: possible involvement of proto-oncogenes c-jun and c-fos. Arterioscler. Thromb. 11: 1042-1052
291. Slivka S. R. and Loskutoff D. J. (1991) Regulation of type 1 plasminogen activator inhibitor synthesis by protein kinase C and cAMP in bovine aortic endothelial cells. Biochim. Biophys. Acta 1094: 317-322
292. Thalacker F. W. and Nilsen-Hamilton M. (1992) Opposite and independent actions of cyclic AMP and transforming growth factor beta in the regulation of type 1 plasminogen activator inhibitor expression. Biochem. J. 287: 855-862
293. Knudsen IL, Olesen T., Riccio A., Ungaro P., Christensen L. and Andreasen P. A. (1994) A common response element mediates differential effects of phorbol esters and forskolin on type-1 plasminogen activator inhibitor gene expression in human breast carcinoma cells. Eur. J. Biochem. 220: 63-74
294. Sassone-Corsi P., Visvader J., Ferland L., Mellon P. L. and Verma I. M. (1988) Induction of proto-oncogene fos transcription through the adenylate cyclase pathway: characterization of a cAMP-responsive element. Genes Dev. 2: 1529-1538
295. Fukumoto S., Allan E. H., Zeheb R., Gelehrter T. D. and Martin T. J. (1992) Glucocorticoid regulation of plasminogen activator inhibitor-1 messenger ribonucleic acid and protein in normal and malignant rat osteoblasts. Endocrinology 130: 797-804
296. Heaton J. H., Kathju S. and Gelehrter T. D. (1992) Transcriptional and posttranscriptional regulation of type 1 plasminogen activator inhibitor and tissue-type plasminogen activator gene expression in HTC rat hepatoma cells by glucocorticoids and cyclic nucleotides. Mol. Endocrinol. 6: 53-60
297. Andreasen P. A., Georg B., Lund L. R., Riccio A. and Stacey S. N. (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell Endocrinol. 68: 1-19
298. Mayer M. (1990) Biochemical and biological aspects of the plasminogen activation system. Clin. Biochem. 23: 197-211
299. Zonneveld A. J. van, Curriden S. A. and Loskutoff D. J. (1988) Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc. Natl. Acad. Sci. USA 85: 5525-5529
300. Bruzdzinski C. J., Johnson M. R., Goble C. A., Winograd S. S. and Gelehrter T. D. (1993) Mechanism of glucocorticoid induction of the rat plasminogen activator inhibitor-1 gene in HTC rat hepatoma cells: identification of cis-acting regulatory elements. Mol. Endocrinol. 7: 1169-1177
301. Juhan-Vague J., Alessi M. C. and Vague P. (1996) Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann. Med. 28: 371-380
302. Panahloo A. and Yudkin J. S. (1997) Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease. J. Cardiovasc. Risk. 4: 91-99
303. Nordt T. K., Klassen K. J., Schneider D. J. and Sobel B. E. (1993) Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioseler. Thromb. 13: 1822-1828
304. Chen Y. Q., Su M., Walia R. R., Hao Q., Covington J. W. and Vaughan D. E. (1998) Spl sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J. Biol. Chem. 273: 8225-8231
305. Daniel S., Zhang S., DePaoli-Roach A. A. and Kim K. H. (1996) Dephosphorylation of Spl by protein phosphatase 1 is involved in the glucose-mediated activation of the acetyl-CoA carboxylase gene. J. Biol. Chem. 271: 14692-14697
306. Pyke C., Kristensen P., Ralfkiaer E., Eriksen J. and Dano K. (1991) The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 51: 4067-4071
307. Heiss M. M., Babie R., Allgayer H., Gruetzner K. U., Jauch K. W., Loehrs U. et al. (1995) Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol. 13: 2084-2093
308. Kunz C., Pebler S., Otte J. and Ahe D. von der (1995) Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res. 23: 3710-3717
309. Eriksson P., Kallin B., Hooft F. M. van't, Bavenholm P. and Hamsten A. (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA 92: 1851-1855
310. Dawson S. J., Wiman B., Hamsten A., Green F., Humphries S. and Henney A. M. (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem. 268: 10739-10745
311. Ryan M. P., Kutz S. M. and Higgins P. J. (1996) Complex regulation of plasminogen activator inhibitor type-1 (PAI-1) gene expression by serum and substrate adhesion. Biochem. J. 314: 1041-1046
312. Nevins J. R. (1992) Transcriptional regulation: a closer look at E2F. Nature 358: 375-376
313. Farnham P. J., Slansky J. E. and Kollmar R. (1993) The role of E2F in the mammalian cell cycle. Biochim. Biophys. Acta 1155: 125-131
314. Emeis J. J. and Kooistra T. (1986) Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J. Exp. Med. 163: 1260-1266
315. Fearns C. and Loskutoff D. J. (1997) Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide: cellular localization and role of endogenous tumor necrosis factor-alpha. Am. J. Pathol. 150: 579-590
316. Seki T. and Gelehrter T. D. (1996) Interleukin-1 induction of type-1 plasminogen activator inhibitor (PAI-1) gene expression in the mouse hepatocyte line, AML 12. J. Cell Physiol. 168: 648-656
317. Yamashita M. (1997) Tumor necrosis factor alpha is involved in the induction of plasminogen activator inhibitor-1 by endotoxin. Thromb. Res. 87: 165-170
318. Hopkins W. E., Westerhausen D. R. Jr., Sobel B. H. and Billadello J. J. (1991) Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA
319. Ushiro S., Ono M., Izumi H., Kohno K., Taniguchi N., Higashiyama S. et al. (1996) Heparin-binding epidermal growth factor-like growth factor: p91 activation induction of plasminogen activator/inhibitor, and tubular morphogenesis in human microvascular endothelial cells. Jpn. J. Cancer Res. 87: 68-77
320. Pepper M. S., Ferrara N., Orci L. and Montesano R. (1991) Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181: 902-906
321. Olofsson B., Korpelainen E., Pepper M. S., Mandriota S. J., Aase K., Kumar V. et al. (1998) Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA 95: 11709-11714
322. Sandberg T., Eriksson P., Gustavsson B. and Casslen B. (1997) Differential regulation of the plasminogen activator inhibitor-1 (PAI-1) gene expression by growth factors and progesterone in human endometrial stromal cells. Mol. Hum. Reprod. 3: 781-787
323. Ye R. D., Ahern S. M., Le Beau M. M., Lebo R. V. and Sadler J. E. (1989) Structure of the gene for human plasminogen activator inhibitor-2: the nearest mammalian homologue of chicken ovalbumin. J. Biol. Chem. 264: 5495-5502
324. Kruithof E. K. and Cousin E. (1988) Plasminogen activator inhibitor 2: isolation and characterization of the promoter region of the gene. Biochem. Biophys. Res. Commun. 156: 383-388
325. Dear A. E., Shen Y., Ruegg M. and Medcalf R. L. (1996) Molecular mechanisms governing tumor-necrosis-factor-mediated regulation of plasminogen-activator inhibitor type-2 gene expression. Eur. J. Biochem. 241: 93-100
326. Kyriakis J. M. and Avruch J. (1996) Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 18: 567-577
327. Saklatvala J., Davis W. and Guesdon F. (1996) Interleukin 1 (ILI) and tumour necrosis factor (TNF) signal transduction. Phil. Trans. R. Soc. Lond. B. 351: 151-157
328. Lee F. S., Hagler J., Chen Z. J. and Maniatis T. (1997) Activation of the IkappaB alpha kinase complex by MEKKI, a kinase of the JNK pathway. Cell 88: 213-222
329. Giezen J. J. van, Brakkee J. G., Dreteler G. H., Bouma B. N. and Jansen J. W. (1994) Dexamethasone affects platelet aggregation and fibrinolytic activity in rats at different doses which is reflected by their effect on arterial thrombosis. Blood Coagul. Fibrinolysis 5: 249-255
330. Antalis T. M., Costelloe E., Muddiman J., Ogbourne S. and Donnan K. (1996) Regulation of the plasminogen activator inhibitor type-2 gene in monocytes: localization of an upstream transcriptional silencer. Blood 88: 3686-3697
331. Soravia E., Grebe A., De Luca P., Helin K., Suh T. T., Degen J. L. et al. (1995) A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. Blood 86: 624-635
332. Suh T. T., Nerlov C., Dano K. and Degen J. L. (1994) The murine urokinase-type plasminogen activator receptor gene. J. Biol. Chem. 269: 25992-25998
333. Rauscher F. J. D. (1993) Tumor suppressor genes which encode transcriptional repressors: studies on the EGR and Wilms' tumor (WTI) gene products. Adv. Exp. Med. Biol. 348: 23-29
334. Liu C., Calogero A., Ragona G., Adamson E. and Mercola D. (1996) EGR-1. the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity. Crit. Rev. Oncogen. 7: 101-125
335. Lund L. R., Romer J., Ronne E., Ellis V., Blasi F. and Dano K. (1991) Urokinase-receptor biosynthesis mRNA level and gene transcription arc increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. EMBO J. 10: 3399-3407
336. Lund L. R., Ronne E., Roldan A. L., Behrendt N., Romer J., Blasi F. et al. (1991) Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J. Biol. Chem. 266: 5177-5181
337. Wang Y., Jones C. J., Dang J., Liang X., Olsen J. E. and Doe W. F. (1994) Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett. 353: 138-142
338. Niiya K., Ozawa T., Tsuzawa T., Ueshima S., Matsuo O. and Sakuragawa N. (1998) Transcriptional regulation of urokinase-type plasminogen activator receptor by cyclic AMP in PL-21 human myeloid leukemia cells; comparison with the regulation by phorbol myristate acetate. Thromb. Haemost. 79: 574-578
339. Speth C., Pichler I., Stockl G., Mair M. and Dierich M. P. (1998) Urokinase plasminogen activator receptor (uPAR: CD87) expression on monocytic cells and T cells is modulated by HIV-1 infection. Immunobiology 199: 152-162
340. Lengyel E., Wang H., Stepp E., Juarez J., Wang Y., Doe W. et al. (1996) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J. Biol. Chem. 271: 23176-23184
341. Banks E. B., Crish J. F., Welter J. F. and Eckert R. L. (1998) Characterization of human involucrin promoter distal regulatory region transcriptional activator elements a role for Spl and API binding sites, Biochem J. 331: 61-68
342. Allgayer H., Wang H., Wang Y., Heiss M. M., Bauer R., Nyormoi O. et al. (1999) Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif hound with an activator protein-2alpha-related factor. J. Biol. Chem. 274: 4702-4714
343. Gum R., Juarez J., Allgayer H., Mazar A., Wang Y. and Boyd D. (1998) Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules. Oncogene 17: 213-225
344. Muhlrad D., Decker C. J. and Parker R. (1994) Deadenylation of the unstable mRNA encoded by the yeast MFA2 gene leads to decapping followed by 5′ to 3′ digestion of the transcript. Genes Dev. 8: 855-866
345. Beelman C. A. and Parker R. (1995) Degradation of mRNA in eukaryotes. Cell 81: 179-183
346. Caponigro G. and Parker R. (1995) Multiple functions for the poly(A)-binding protein in mRNA decapping and dead-enylation in yeast. Genes Dev. 9: 2421-2432
347. LaGrandeur T. E. and Parker R. (1998) Isolation and characterization of Deplp. the yeast mRNA decapping enzyme. EMBO J. 17: 1487-1496
348. Beelman C. A., Stevens A., Caponigro G., LaGrandeur T. E., Hatfield L., Fortner D. M. et al. (1996) An essential component of the decapping enzyme required for normal rates of mRNA turnover. Nature 382: 642-646
349. Muhlrad D. and Parker R. (1994) Premature translational termination triggers mRNA decapping. Nature 370: 578-581
350. Anderson J. S. J. and Parker R. P. (1998) The 3′ to 5′ degradation of yeast mRNAs is a general mechanism for mRNA turnover that requires the SKI2 DEVH box protein and 3′ to 5′ exonucleases of the exosome complex. EMBO J. 17: 1497-1506
351. Shyu A.-B., Belasco J. G. and Greenberg M. E. (1991) Two distinct destabilizing elements in the c-fos message trigger deadenylation as a first step in rapid mRNA decay. Genes Dev. 5: 221-231
352. Ross J. (1995) mRNA stability in mammalian cells. Microbiol. Rev. 59: 423-450
353. Korner C. G. and Wahle E. (1997) Poly(A) tail shortening by a mammalian poly(A)-specific 3′-exoribonuclease. J. Biol. Chem. 272: 10448-10456
354. Couttel P., Fromont-Racine M., Steel D., Pietel R. and Grange T. (1997) Messenger RNA deadenylylation precedes decapping in mammalian cells. Proc. Natl. Acad. Sci. USA 94: 5628-5633
355. Bashkirov V. I., Scherthan H., Solinger J. A., Buerstedde J. M. and Heyer W. D. (1997) A mouse cytoplasmic exonbonuclease (mXRN 1p) with preference for G4 tetraplex substrates. J. Cell Biol. 136: 761-773
356. Somoskeoy S., Rao M. N. and Slobin L. I. (1996) Purification and characterization of a 5′ to 3′ exoribonuclease from rabbit reticulocytes that degrades capped and uncapped RNAs. Eur. J. Biochem. 237: 171-179
357. Sachs A. B. and Deardorff J. A. (1992) Translation initiation requires the PAB-dependent poly(A) ribonuclease in yeast. Cell 70: 961-973
358. Tarun S. Z. Jr. and Sachs A. B. (1996) Association of the yeast poly(A) tail binding protein with translation initiation factor eIF-4G. EMBO J. 15: 7168-7177
359. Craig A. W., Haghighat A., Yu A. T. and Sonenberg N. (1998) Interaction of polyadenylate-binding protein with the cIF4G homologue PAIP enhances translation. Nature 392: 520-523
360. Chen Y. R. and Tan T. H. (1998) Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17: 173-178
361. Chen C. Y. and Shyu A. B. (1995) AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 20: 465-470
362. Xu N., Loflin P., Chen C. Y. and Shyu A. B. (1998) A broader role for AU-rich element-mediated mRNA turnover revealed by a new transcriptional pulse strategy. Nucleic Acids Res. 26: 558-565
363. Zubiaga A., Belasco J. and Greenberg M. (1995) The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol. Cell. Biol. 15: 2219-2230
364. Lagnado C. A., Brown C. Y. and Goodall G. J. (1994) AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: the functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A). Mol. Cell Biol. 14: 7984-7995
365. Katz. D. A., Theodorakis N. G., Cleveland D. W., Lindsten T. and Thompson C. B. (1994) AU-A, an RNA-binding activity distinct from hnRNP Al, is selective for AUUUA repeats and shuttles between the nucleus and the cytoplasm. Nucleic Acids Res. 22: 238-246
366. Bohjanen P. R., Petryniak B., June C. H., Thompson C. B. and Lindsten T. (1991) An inducible cytoplasmic factor (AU-B) binds selectively to AUUUA multimers in the 3′ untranslated region of lymphokine mRNA. Mol. Cell. Biol. 11: 3288-3295
367. Bohjanen P. R., Petryniak B., June C. H., Thompson C. B. and Lindsten T. (1992) AU RNA-binding factors differ in their binding specificities and affinities. J. Biol. Chem. 267: 6302-6309
368. Antic D. and Keene J. D. (1997) Embryonic lethal abnormal visual RNA-binding proteins involved in growth, differentiation, and posttranscriptional gene expression. Am. J. Hum. Genet. 61: 273-278
369. Hamilton B. J., Nagy E., Malter J. S., Arrick B. A. and Rigby W. F. (1993) Association of heterogeneous nuclear ribonucleoprotein Al and C proteins with reiterated AUUUA sequences. J. Biol. Chem. 268: 8881-8887
370. Zhang W., Wagner B. J., Ehrenman K., Schaefer A. W., DeMarie C. T., Crater D. et al. (1993) Purification, characterization, and cDNA cloning of an AU-rich element RNA-binding protein, AUF1. Mol. Cell Biol. 13: 7652-7665
371. Pende A., Tremmel K. D., DeMaria C. T., Blaxall B. C., Minobe W. A., Sherman J. A. et al. (1996) Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway. J. Biol. Chem. 271: 8493-8501
372. Carballo E., Lai W. S. and Blackshear P. J. (1998) Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281: 1001-1005
373. Fan X. C. and Steitz J. A. (1998) Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 17: 3448-3460
374. Levy N. S., Chung S., Furneaux H. and Levy A. P. (1998) Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273: 6417-6423
375. Nair A. P., Hahn S., Banholzer R., Hirsch H. H. and Moroni C. (1994) Cyclosporin A inhibits growth of autocrine tumour cell lines by destabilizing interleukin-3 mRNA. Nature 369: 239-242
376. Banholzer R., Nair A. P., Hirsch H. H., Ming X. F. and Moroni C. (1997) Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3′ untranslated region, Mol. Cell Biol. 17: 3254-3260
377. Casey J. L., Koeller D. M., Ramin V. C., Klausner R. D. and Harford J. B. (1989) Iron regulation of transferrin receptor mRNA levels requires iron-responsive elements and a rapid turnover determinant in the 3′ untranslated region of the mRNA. EMBO J. 12: 3693-3699
378. Mullner E. W., Neupert B. and Kuhn L. (1989) A specific mRNA binding factor regulates iron-dependent stability of cytoplasmic transferrin receptor mRNA. Cell 58: 373-382
379. Wellington C. L., Greenberg M. E. and Belasco J. G. (1993) The destabilizing elements in the coding region of c-fos mRNA are recognized as RNA. Mol. Cell Biol. 13: 5034-5042
380. Wisdom R. and Lee W. (1991) The protein-coding region of c-myc mRNA contains a sequence that specifies rapid mRNA turnover and induction by protein synthesis inhibitors. Genes Dev. 5: 232-243
381. Pachter J. S., Yen T. J. and Cleveland D. W. (1987) Autoregulation of tubulin expression is achieved through specific degradation of polysomal tubulin mRNAs. Cell 51: 283-292
382. Yen T. J., Machlin P. S. and Cleveland D. W. (1988) Autoregulated instability of beta-tubulin mRNAs by recognition of the nascent amino terminus of beta-tubulin. Nature 334: 580-585
383. Altus M. S., Pearson D., Horiuchi A. and Nagamine Y. (1987) Inhibition of protein synthesis in LLC-PK1 cells increases calcitonin-induced plasminogen-activator gene transcription and mRNA stability. Biochem. J. 242: 387-392
384. Altus M. S. and Nagamine Y. (1991) Protein synthesis inhibition stabilizes urokinase-type plasminogen activator mRNA; studies in vivo and in cell-free decay reactions. J. Biol. Chem. 266: 21190-21196
385. Henderson B. R., McDonald D. A. and Kefford R. F. (1992) Post-transcriptional regulation of urokinase plasminogen activator gene expression occurs in the nucleus of BCI rat mammary tumor cells. Int. J. Cancer. 50: 918-923
386. 2+ potentiates cAMP-dependent expression of urokinase-type plasminogen activator gene through a calmodulin- and protein kinase C-independent mechanism. J. Biol. Chem. 265: 21194-21201
387. Ziegler A., Knesel J., Fabbro D. and Nagamine Y. (1991) Protein kinase C down-regulation enhances cAMP-mediated induction of urokinase-type plasminogen activator mRNA in LLC-PK1 cells. J. Biol. Chem. 266: 21067-21074
388. Nanbu R., Menoud P.-A. and Nagamine Y. (1994) Multiple instability-regulating sites in the 3′ untranslated region of the urokinase-type plasminogen activator mRNA. Mol. Cell Biol. 14: 4920-4928
389. Nanbu R., Montero L., D'Orazio D. and Nagamine Y. (1997) Enhanced stability of urokinase-type plasminogen activator mRNA in metastatic breast cancer MDA-MB-231 cells and LLC-PK1 cells down-regulated for protein kinase C correlation with cytoplasmic heterogeneous nuclear ribonucleoprotein C. Eur. J. Biochem. 247: 169-174
390. Wang Y., Dang J., Liang X. and Doe W. F. (1995) Amiloride modulates urokinase gene expression at both transcription and post-transcription levels in human colon cancer cells. Clin. Exp. Metastasis 13: 196-202
391. Vassalli J. D. and Belin D. (1987) Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 214: 187-191
392. Henderson B. R., Tansey W. P., Phillips S. M., Ramshaw I. A. and Kefford R. F. (1992) Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Cancer Res. 52: 2489-2496
393. Henderson B. R. and Kefford R. F. (1993) Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells. Br. J. Cancer 67: 99-101
394. Gaido K. W. and Maness S. C. (1995) Post-transcriptional stabilization of urokinase plasminogen activator mRNA by 2,3,7,8-tetrachlorodibenzo-p-dioxin in a human keratinocyte cell line. Toxicol. Appl. Pharmacol. 133: 34-42
395. Vassalli J. D., Huarte J., Belin D., Gubler P., Vassalli A., O'Connell M. L. et al. (1989) Regulated polyadenylation controls mRNA translation during meiotic maturation of mouse oocytes. Genes Dev. 3: 2163-2171
396. Huarte J., Stutz A., O'Connell M. L., Gubler P., Belin D., Darrow A. I., et al. (1992) Transient translational silencing by reversible mRNA deadenylation. Cell 69: 1021-1030
397. Huarte J., Belin D., Vassalli A., Strickland S. and Vassalli J. D. (1987) Meiotic maturation of mouse oocytes triggers the translation and polyadenylation of dormant tissue-type plasminogen activator mRNA. Genes Dev. 1: 1201-1211
398. Stutz A., Huarte J., Gubler P., Conne B., Belin D. and Vassalli J. D. (1997) In vivo antisense oligodeoxynucleotide mapping reveals masked regulatory elements in an mRNA dormant in mouse oocytes. Mol. Cell Biol. 17: 1759-1767
399. Stutz A., Conne B., Huarte J., Gubler P., Volkel V., Flandin P. et al. (1998) Masking, unmasking, and regulated polyadenylation cooperate in the translational control of a dormant mRNA in mouse oocytes. Genes Dev. 12: 2535-2548
400. Ginsburg D., Zeheb R., Yang A. Y., Rafferty U. M., Andreasen P. A., Nielsen L. et al. (1986) cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J. Clin. Invest. 78: 1673-1680
401. Ny T., Sawdey M., Lawrence D., Millan J. L. and Loskutoff D. J. (1986) Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA 83: 6776-6780
402. Bosma P. J. and Kooistra T. (1991) Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells. J. Biol. Chem. 266: 17845-17849
403. Juhan-Vague I., Alessi M. C., Joly P., Thirion X., Vague P., Declerck P. J. et al. (1989) Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of plasma insulin and acute-phase response. Arteriosclerosis 362-367
404. Schneider D. J. and Sobel B. E. (1991) Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type 1: implications for vascular disease in hyperinsulinemic states. Proc. Natl. Acad. Sci. USA 88: 9959-9963
405. Fattal P. G., Schneider D. J., Sobel B. E. and Billadello J. J. (1992) Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J. Biol. Chem. 267: 12412-12415
406. Heaton J. H., Tillmann-Bogush M., Leff N. S. and Gelehrter T. D. (1998) Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells: identification of cis-acting sequences. J. Biol. Chem. 273: 14261-14268
407. Tillmann-Bogush M., Heaton J. H. and Gelehrter T. D. (1999) Cyclic nucleotide regulation of PAI-1 mRNA stability: identification of cytosolic proteins that interact with an A-rich sequence. J. Biol. Chem. 274: 1172-1179
408. Chuang T. H., Hamilton R. T. and Nilsen-Hamilton M. (1995) Cloning of the mink plasminogen activator inhibitor type-1 messenger RNA: an mRNA with a short half life. Gene 162: 303-308
409. Maurer F. and Medcalf R. L. (1996) Plasminogen activator inhibitor type 2 gene induction by tumor necrosis factor and phorbol ester involves transcriptional and post-transcriptional events: identification of a functional nonameric AU-rich motif in the 3′-untranslated region. J. Biol. Chem. 271: 26074-26080
410. Shetty S., Kumar A. and Idell S. (1997) Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol. Cell Biol. 17: 1075-1083
411. Lund I., R., Ellis V., Ronne E., Pyke C. and Dano K. (1995) Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem. J. 310: 345-352
412. Wang G. J., Collinge M., Blasi F., Pardi R. and Bender J. R. (1998) Posttranscriptional regulation of urokinase plasminogen activator receptor messenger RNA levels by leukocyte integrin engagement. Proc. Natl. Acad. Sci. USA 95: 6296-6301